Abstract Number: 2332 • ACR Convergence 2025
Development and validation of a Disease Activity index for PSoriatic Arthritis based on 44 joints: DAPSA44
Background/Purpose: Recent studies have highlighted the potential of composite scores such as the DAPSA for assessing peripheral arthritis in axSpA and pSpA. However, the swollen…Abstract Number: 2124 • ACR Convergence 2025
Reliability and Validation of the Physician’s Global Assessment of Lung Disease (PGALD) in Systemic Juvenile Idiopathic Arthritis -Associated Lung Disease (SJIA-LD)
Background/Purpose: The physician global assessment of lung disease (PGALD) is a recently proposed disease activity measure for patients with systemic juvenile idiopathic arthritis-associated lung disease…Abstract Number: 1536 • ACR Convergence 2025
Evaluating Systemic Lupus Erythematosus Remission Among Patients Initiating Belimumab in a Real-World Setting in the USA
Background/Purpose: The Definition Of Remission In SLE (DORIS) criteria were developed to provide alignment on defining remission in patients with SLE.1,2 Belimumab (BEL) treatment increases…Abstract Number: 1409 • ACR Convergence 2025
The impact of depression in axial spondyloarthritis: Epidemiological insights from the Ankylosing Spondylitis Registry of Ireland (ASRI)
Background/Purpose: The burden of comorbidities in Axial Spondyloarthritis (axSpA) is increasingly recognised and contributes to the concept of difficult-to-treat axSpA (D2T-axSpA). The need to assess…Abstract Number: 1159 • ACR Convergence 2025
IL-18 Correlates with Pouchot Score and Inflammatory Biomarkers in Adult-Onset Still’s Disease: Insights From a Repeated Measures Study
Background/Purpose: Adult-Onset Still’s Disease (AOSD) is a rare systemic inflammatory disease. Interleukin-18 (IL-18) levels are significantly elevated in AOSD patients¹ and may be a promising…Abstract Number: 0834 • ACR Convergence 2025
Heterogeneity in the Association of Genetic Risk for Rheumatoid Arthritis and Resultant Rheumatoid Arthritis Phenotypes
Background/Purpose: The impact of genetic risk factors on rheumatoid arthritis (RA) phenotype is incompletely understood. Comparing individual genetic variants associated with RA susceptibility to a…Abstract Number: 0473 • ACR Convergence 2025
A Phase 2b Dose-Ranging Study of Peresolimab for Adults with RA
Background/Purpose: Peresolimab, a humanized IgG1 mAb, activates programmed cell death protein 1. In a phase 2a study, peresolimab demonstrated efficacy in participants (pts) with RA…Abstract Number: 0295 • ACR Convergence 2025
Multidimensional Analysis of Fatigue in Idiopathic Inflammatory Myopathies: Clinical, Psychological, and Sociodemographic Determinants
Background/Purpose: Fatigue significantly impacts quality of life in idiopathic inflammatory myopathies (IIM) but remains poorly understood. This study aimed to identify the key determinants of…Abstract Number: 2649 • ACR Convergence 2025
Simultaneous Assessment of Complementary Lupus-Specific Immune Mediator-Informed Indexes Improves Their Ability to Concurrently Discern Current Disease Activity And Future Flare Risk In Systemic Lupus Erythematosus
Background/Purpose: Immune dysregulation propels systemic lupus erythematosus (SLE) pathogenesis. Capturing it as lab-based screening tests could help prioritize SLE patients for early intervention and proactive…Abstract Number: 2322 • ACR Convergence 2025
Gender-related Differences in Peripheral and Axial Spondyloarthritis
Background/Purpose: This study sought to compare clinical characteristics between female and male patients with spondyloarthritis (SpA) in a Turkish population.Methods: This study included 489 peripheral…Abstract Number: 2096 • ACR Convergence 2025
Gamification and Social Incentivization to Promote Physical Activity in Adults with Knee Osteoarthritis: Results from a Multi-Site Randomized Trial
Background/Purpose: Promotion of physical activity is important in the management of knee osteoarthritis (KOA), though effective strategies for behavioral change to promote exercise are lacking.…Abstract Number: 1533 • ACR Convergence 2025
Belimumab Is Associated with Early Improvement in Disease Activity Measures Among Patients with Systemic Lupus Erythematosus in the US
Background/Purpose: Belimumab (BEL), a B-cell modulator mAb that selectively inhibits soluble B-lymphocyte stimulator and reduces autoreactive B cells that drive lupus disease activity, is approved…Abstract Number: 1396 • ACR Convergence 2025
Influence of Age on Daily Impairment, Patient Empowerment, Activation and Engagement in Patients with Sjögren’s Disease
Background/Purpose: Patient-centred care and improvement of daily life are the main components in chronic disease management. The aim of the study was to determine associations…Abstract Number: 1149 • ACR Convergence 2025
Patient Symptom State Demonstrates Validity for the Assessment of Disease Activity and Patient-reported Outcomes in Adults with SAPHO and Chronic Nonbacterial Osteomyelitis – A Longitudinal Response Profile Analysis in The SAPHO-CNO Study
Background/Purpose: Patient symptoms are important in the assessment of disease activity. The Patient Acceptable Symptom State (PASS) is defined as the minimum symptom score beyond…Abstract Number: 0805 • ACR Convergence 2025
Safety and Efficacy of Hydroxychloroquine According to Weight-based Dose: Results of a Global Systematic Review and Meta-analysis
Background/Purpose: Hydroxychloroquine (HCQ) is a foundational therapy in systemic lupus erythematosus (SLE) treatment, as it prolongs disease-free and damage-free survival. However, the optimal dose is…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 112
- Next Page »
